| Outcome Measures: |
Primary: Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing, 12 hours | Secondary: INS-Area Under the Curve (AUC) over 24 and 36 hours after dosing (INS AUC 0-24 and INS AUC 0-36), 36 hours|AUC up to the last measurable concentration, 36 hours|Time to reach 50% of INS-AUC 0-36, 36 hours|Time to reach INS-Cmax (INS-tmax), 36 hours|Area under the body-weight-standardized Glucose Infusion Rate (GIR) over the first 12, 24 and 36 hours after dosing (GIR-AUC0-12, GIR-AUC0-24 and, GIR-AUC0-36), 36 hours|Time to reach 50% of GIR-AUC0-36 (T50%-GIR-AUC0-36), 36 hours|Maximum smoothed body weight standardized glucose infusion rate (GIRmax) and time to GIRmax (GIR-Tmax), 36 hours|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above different pre-specific blood glucose levels), 4 days|Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters), 4 days
|
